EPO-regulated reduction of lipogenic genes could potentially help reduce fat synthesis that is associated with high triglyceride levels in liver and adipose tissues in metabolic disease or obesity [102]. This evidence concerns the gene EPO and obesity due to melanocortin 4 receptor deficiency.